Banking Law and Multinational Nanotechnology Ventures in Spain

1. Introduction

“Banking Law and Multinational Nanotechnology Ventures” is not a single statutory field in Spain. It is a cross-disciplinary legal area in which banking regulation, corporate finance, intellectual property, foreign investment, technology regulation, environmental and product-safety rules, and EU law can overlap.

A multinational nanotechnology company operating in Spain may need financing from Spanish or international banks, establish Spanish subsidiaries, license patents, receive foreign investment, commercialise products, and potentially use financial or technology platforms regulated by Spanish authorities.

Spanish financial regulation is organised around several institutions. Banco de España maintains the principal framework for credit institutions and prudential banking regulation, while the CNMV supervises securities markets and investment services. Spain also has a financial-innovation framework under Law 7/2020, which created a controlled regulatory sandbox for technology-based innovation affecting the financial system.

For a nanotechnology venture, the central legal question is therefore:

How can a technologically advanced multinational enterprise obtain and use banking and investment finance in Spain while protecting its technology and complying with Spanish and EU regulatory requirements?

2. Banking Law Relevant to Nanotechnology Ventures

A nanotechnology company is normally not itself a “bank” merely because it receives financing from banks.

Its ordinary relationship with banking law is therefore primarily through:

corporate borrowing;

investment financing;

project finance;

working-capital facilities;

acquisition finance;

guarantees;

securities offerings;

payment services;

foreign-exchange transactions;

investment management; and

financial-market transactions.

If the company itself begins providing regulated financial services, however, it may enter a substantially different regulatory category.

Spain's principal banking-supervision framework includes Law 10/2014 on the regulation, supervision and solvency of credit institutions, together with EU prudential legislation such as the Capital Requirements Regulation.

3. Corporate Structure

A multinational nanotechnology group entering Spain will normally choose an appropriate corporate structure.

Possible structures include:

Spanish subsidiary

The foreign parent establishes a Spanish company that conducts the research, manufacturing or commercial operation.

Spanish branch

The foreign company directly establishes an operational branch in Spain.

Joint venture

The multinational collaborates with a Spanish technology company, university, research institution or industrial partner.

Acquisition

The multinational purchases an existing Spanish technology company.

The corporate structure matters to banks because it determines who:

borrows the money;

owns the intellectual property;

provides security;

guarantees repayment;

bears operational liabilities; and

prepares financial statements.

4. Bank Financing

A Spanish bank financing a nanotechnology venture will normally evaluate ordinary credit factors together with technology-specific risks.

These may include:

cash flow;

business plan;

existing debt;

intellectual-property assets;

research expenditure;

regulatory approvals;

commercial contracts;

manufacturing capacity;

insurance;

management structure; and

financial support from the multinational parent.

For an early-stage nanotechnology company, traditional asset-based lending may be difficult because much of its value may consist of intellectual property rather than buildings or conventional physical assets.

Consequently, financing may involve:

equity + venture capital + bank debt + grants + strategic investment.

5. Intellectual Property as a Financing Asset

Nanotechnology ventures can have substantial intellectual-property value.

Important assets may include:

patents;

patent applications;

industrial designs;

trade secrets;

proprietary manufacturing processes;

software;

databases; and

know-how.

A bank or investor may therefore need to understand the ownership and enforceability of the company's intellectual property before providing substantial financing.

The legal value of the technology can be particularly important where the company has relatively few tangible assets.

6. Patent Protection

Nanotechnology inventions may involve materials, manufacturing techniques, devices, chemical processes or applications at the nanoscale.

Patentability must be considered under the relevant Spanish and European patent framework.

A central principle of European patent law is that a patent protects an invention, not merely a scientific discovery.

The invention generally needs to satisfy requirements such as:

novelty;

inventive step; and

industrial applicability.

For a multinational company, patent strategy is usually international rather than limited to Spain.

The company may therefore need to coordinate:

Spanish protection + European patent protection + protection in other important markets.

7. Important Intellectual-Property Case Law

Case 1 — Spain v Council, C-147/13

In Spain v Council (C-147/13), Spain challenged the EU framework establishing enhanced cooperation concerning unitary patent protection.

The CJEU dismissed Spain's challenge.

Importance for nanotechnology

The case demonstrates the importance of the EU patent framework for businesses whose technology requires protection across several European markets.

A multinational nanotechnology company can therefore consider European patent strategies rather than treating every European market as completely isolated.

8. Netherlands v Parliament and Council — C-377/98

This major CJEU decision concerned the Biotechnology Directive.

The Court upheld the EU framework governing the legal protection of biotechnological inventions. It considered questions concerning patentability, human dignity and the limits of biotechnology patents.

Relevance

Although biotechnology is not identical to nanotechnology, the case illustrates an important principle:

advanced scientific technology can be commercially valuable while still being subject to legal limitations concerning patentability and public policy.

A nanotechnology business must therefore distinguish between a commercially interesting scientific discovery and a legally protectable invention.

9. International Stem Cell Corporation — C-364/13

In International Stem Cell Corporation (C-364/13), the CJEU interpreted the EU Biotechnology Directive concerning patentability and the meaning of “human embryo.”

The Court held that an unfertilised human ovum activated through parthenogenesis did not constitute a human embryo for the relevant provision where, according to current scientific knowledge, it did not have the inherent capacity to develop into a human being.

Relevance

For advanced-technology enterprises, this case demonstrates that patent law can depend upon detailed scientific characteristics.

It also shows that the legal treatment of emerging technologies may require close examination of the underlying scientific facts.

10. Abraxis Bioscience — C-443/17

In Abraxis Bioscience (C-443/17), the CJEU considered the interpretation of EU supplementary protection certificate rules concerning medicinal products.

Relevance

A nanotechnology company developing medical or pharmaceutical applications may encounter similar issues concerning the relationship between:

patent protection → regulatory approval → commercial exploitation → additional intellectual-property protection.

The case is not a nanotechnology case, but its legal reasoning can be relevant to advanced technology ventures operating in regulated healthcare markets.

11. Financing and Intellectual-Property Due Diligence

Before financing a nanotechnology venture, a bank or investor may investigate:

Who owns the patents?

Are inventions assigned to the Spanish subsidiary or foreign parent?

Are researchers contractually obliged to assign inventions?

Are patents already pledged or licensed?

Are there competing patent claims?

Is the technology subject to university or research-institution rights?

Are important manufacturing processes protected as trade secrets?

This matters because a financing institution does not want to lend against an asset whose ownership is uncertain.

12. Trade Secrets

Nanotechnology businesses may possess commercially valuable information that cannot easily be patented.

Examples include:

production parameters;

chemical formulations;

manufacturing tolerances;

experimental data;

process know-how;

supplier information; and

proprietary research methods.

Such information may be protected through trade-secret law and contractual confidentiality.

For a multinational group, internal information-sharing arrangements must therefore be carefully structured.

13. Cross-Border Investment

Multinational nanotechnology ventures may involve substantial foreign investment into Spain.

For example:

A Japanese company may invest in a Spanish nanomaterials manufacturer.

A US technology company may establish a Spanish R&D subsidiary.

A European investment fund may acquire an interest in a Spanish nanotechnology company.

These transactions can involve Spanish corporate law, EU capital-movement principles and, depending on the transaction, Spanish foreign-investment screening rules.

14. Foreign Investment Screening

Spain has mechanisms for screening certain foreign investments in strategic sectors.

The purpose is not to prohibit international investment generally.

Rather, certain investments may receive additional scrutiny where they raise concerns relating to public order, public security or strategic interests.

Advanced technologies can become relevant to such analysis where the technology has strategic or dual-use characteristics.

Therefore, multinational nanotechnology companies should distinguish between:

ordinary foreign investment

and

foreign investment potentially subject to screening or prior authorisation.

15. Case 5 — Commission v Spain, C-463/00

In Commission v Spain (C-463/00), the CJEU examined Spanish restrictions affecting acquisition of shareholdings in strategic enterprises.

The Court treated restrictions on capital movements as subject to EU free-movement principles and examined whether restrictions could be justified.

Relevance

The case demonstrates that national measures affecting foreign investment must comply with applicable EU free-movement principles, subject to recognised public-interest justifications.

For a multinational nanotechnology venture, the lesson is that foreign-investment regulation must be considered alongside EU capital-movement rules.

16. Banking Due Diligence

Banks financing a multinational technology venture normally need to understand the entire group.

The bank may examine:

parent-company guarantees;

ownership structure;

beneficial ownership;

intellectual-property ownership;

foreign subsidiaries;

outstanding litigation;

tax exposure;

regulatory approvals;

technology licences;

commercial contracts; and

environmental or product liabilities.

The more complicated the multinational structure, the more important group-level due diligence becomes.

17. Technology and Financial Innovation

A nanotechnology company could also develop technology directly relevant to financial services.

For example, it could develop nanoscale security components used in:

payment cards;

authentication devices;

sensors;

secure hardware;

banknote technologies; or

financial-sector cybersecurity.

If the technology is used within a financial service, additional financial-sector regulation may become relevant.

Spain's Law 7/2020 on the digital transformation of the financial system created a controlled testing environment for technology-based financial innovation.

18. Regulatory Sandbox

The Spanish financial sandbox allows controlled testing of technological projects that can affect financial markets or financial services.

The framework involves relevant authorities including:

Banco de España;

CNMV; and

the Directorate-General for Insurance and Pension Funds,

depending on the nature of the project.

The sandbox is governed by the general statutory framework and a specific testing protocol.

Important safeguards include:

informed consent;

data protection;

participant withdrawal rights;

promoter liability;

confidentiality;

supervisory monitoring; and

the ability to interrupt testing in appropriate circumstances.

For a nanotechnology company developing technology with a direct financial application, this can provide a controlled route for testing the financial use case.

19. Case 6 — Fundación Tatiana Pérez de Guzmán el Bueno and Others v SRB — C-551/22 P

In Case C-551/22 P, the CJEU considered litigation concerning the resolution of Banco Popular and the Single Resolution Mechanism.

The case involved questions concerning the legal status and challengeability of EU banking-resolution measures.

Relevance

For technology companies dependent upon bank financing, banking stability is commercially important.

A company borrowing from a bank needs to understand that the banking institution itself operates within a prudential and resolution framework.

Consequently, major corporate financing arrangements can be affected indirectly by banking-sector regulation.

20. Case 7 — Banco Santander, C-687/23

In Banco Santander (Resolution of Banco Popular III), C-687/23, the CJEU considered issues concerning banking resolution, capital instruments and investor claims following the resolution of Banco Popular. The case originated from the Spanish Supreme Court.

Relevance

The case demonstrates the interaction between:

banking regulation → resolution law → investor rights → contractual claims.

For a multinational technology company raising funds through regulated financial markets or dealing extensively with banks, understanding these institutional risks is important.

21. Case 8 — Caixabank and Spanish Banking Regulation, STC 55/2022

The Spanish Constitutional Court's Judgment 55/2022 concerned Caixabank's challenge involving the tax on deposits held by credit institutions in the Canary Islands.

The case involved questions concerning equality and the application of a statutory tax provision to a credit institution.

Relevance

The decision illustrates that banks operating in Spain may be affected by not only prudential banking rules but also tax and territorial regulatory measures.

A nanotechnology company financing itself through Spanish banks must therefore consider the broader regulatory environment affecting its banking counterparties.

22. Banking Covenants

A major financing agreement may contain financial and operational covenants.

For a nanotechnology company, these could concern:

minimum cash;

maximum indebtedness;

maintenance of insurance;

restrictions on asset sales;

intellectual-property ownership;

changes in control;

major acquisitions;

disposal of important patents; and

material regulatory breaches.

The bank may require notification if the company loses a key patent or faces a major regulatory investigation.

23. Intellectual Property as Collateral

In principle, intellectual property can form part of the economic security package for financing.

However, banks generally need to assess whether the asset is:

legally owned;

transferable;

enforceable;

commercially valuable;

adequately documented; and

capable of being realised if the borrower defaults.

This is more difficult than taking security over a conventional physical asset.

Nanotechnology financing therefore frequently requires specialised legal and valuation due diligence.

24. Environmental and Product Regulation

Nanomaterials can trigger additional regulatory considerations depending upon their characteristics and intended use.

A nanotechnology company may need to consider EU and Spanish rules relating to:

chemicals;

workplace safety;

environmental protection;

consumer products;

medical devices;

pharmaceuticals;

food;

cosmetics; and

industrial manufacturing.

These requirements can directly affect financing.

A bank may consider regulatory compliance a condition for continued lending because regulatory failure could substantially reduce the value of the financed business.

25. ESG and Sustainability Financing

Nanotechnology projects may also seek:

green loans;

sustainability-linked loans;

climate-transition financing; or

specialised technology investment.

Where financing is linked to sustainability targets, the borrower may have contractual reporting obligations.

The company may have to provide evidence concerning:

energy consumption;

emissions;

waste;

resource efficiency;

environmental performance; or

achievement of agreed sustainability indicators.

Misrepresenting such information can create contractual and regulatory consequences.

26. Securities Financing

A mature multinational nanotechnology company may raise money through securities rather than bank loans.

Possible structures include:

equity issuance;

corporate bonds;

convertible securities;

private placements; or

admission of securities to a regulated market.

If securities are offered to the public or admitted to trading, Spanish and EU securities legislation may apply.

The CNMV is the principal Spanish securities-market authority.

Therefore:

bank loan → mainly banking/contractual framework

while

public securities offering → securities-market framework.

A transaction may involve both.

27. Prospectus and Disclosure Risk

A nanotechnology business may have highly technical intellectual-property claims.

Investors need sufficiently accurate information about:

technological maturity;

patents;

commercialisation;

regulatory approvals;

research risks;

financial condition; and

expected revenues.

The more technically complex the business, the more important accurate disclosure becomes.

A company should distinguish clearly between:

proven technology

and

future research expectations.

This distinction can be important in both financing negotiations and securities offerings.

28. Banking, Research and University Partnerships

Spanish nanotechnology ventures may collaborate with universities and research institutions.

This can create questions concerning:

ownership of inventions;

licensing;

research funding;

publication rights;

confidentiality;

patent filing;

background intellectual property; and

commercialisation rights.

Banks and investors may examine these agreements because the commercial value of the business may depend heavily upon university-generated intellectual property.

29. Multinational Group Governance

A multinational nanotechnology group operating in Spain should maintain clear separation between:

Spanish operating company

foreign parent

research subsidiary

IP-holding company

manufacturing entity

and

financing entities.

This becomes especially important where intellectual property is held in one jurisdiction while manufacturing and borrowing occur in another.

Banks will generally want to understand where the assets and cash flows actually reside.

30. Tax and Transfer-Pricing Considerations

Cross-border financing can also create tax issues.

For example, a foreign parent might lend money to its Spanish subsidiary.

The transaction may involve:

interest payments;

transfer-pricing considerations;

withholding-tax questions;

deductibility rules;

thin-capitalisation or interest-limitation rules; and

documentation requirements.

Therefore, multinational financing should not be analysed solely as a banking-law question.

31. AML and Beneficial Ownership

Banks must comply with anti-money-laundering requirements.

When onboarding a multinational nanotechnology group, a financial institution may need to identify:

the legal entity;

beneficial owners;

controlling persons;

source of funds;

business activity;

expected transactions; and

relevant jurisdictions.

Complex corporate structures can therefore increase the bank's compliance requirements.

32. Foreign Currency Financing

A multinational nanotechnology venture may earn revenue in euros but obtain financing in another currency.

This creates:

exchange-rate risk;

hedging requirements;

derivative exposure; and

additional documentation.

A Spanish bank may therefore offer currency hedging alongside the principal financing.

The derivatives themselves can involve additional regulatory requirements.

33. Data Protection and Research Data

Nanotechnology companies can hold large quantities of research and commercial information.

Where personal data are involved, the Spanish company must also consider the GDPR and Spanish data-protection legislation.

Examples include:

employee data;

clinical-research information;

customer information;

supplier data; and

research-participant data.

A financing bank may conduct cybersecurity and data-governance due diligence where data integrity is important to the company's value.

34. Case 9 — Banco Español de Crédito — C-618/10

In Banco Español de Crédito v Calderón Camino (C-618/10), the CJEU examined unfair contractual terms in Spanish consumer credit.

The case established important principles concerning effective judicial protection against unfair contractual terms.

Relevance

The case is primarily a consumer-credit case rather than a corporate nanotechnology-financing case.

Its broader significance is that financial contracts operating in Spain remain subject to mandatory European protections where the relevant legal conditions are satisfied.

For a commercial technology company, the exact consumer protections may not apply in the same way, but the case demonstrates the importance of identifying the legal status of each party to a financial contract.

35. Case 10 — Banco Popular Resolution Litigation

The series of Banco Popular cases before Spanish and EU courts provides an additional lesson for technology companies.

The litigation demonstrates that banking relationships can be affected by European bank-resolution law.

For a company heavily dependent upon one banking institution, the identity and financial condition of the lender can therefore become commercially significant.

A sophisticated financing structure may consequently involve:

multiple lenders;

security-agent arrangements;

alternative funding sources;

parent guarantees; and

contingency provisions.

36. Legal Due-Diligence Checklist

Before obtaining major Spanish financing, a multinational nanotechnology venture should examine:

Corporate

Spanish entity structure;

ownership;

directors;

beneficial ownership;

authority to borrow.

Banking

lender licensing;

loan documentation;

interest;

repayment;

covenants;

guarantees.

Intellectual property

patents;

patent applications;

licences;

ownership;

encumbrances;

trade secrets.

Regulatory

product approvals;

environmental requirements;

chemical regulation;

sector-specific licences.

International

foreign subsidiaries;

parent guarantees;

cross-border loans;

foreign investment rules;

tax.

Data

research data;

personal data;

cybersecurity;

confidentiality.

37. Overall Legal Structure

The relationship can be represented as:

Multinational Parent

↓

Spanish Nanotechnology Company

↓

Research + IP + Manufacturing + Commercial Operations

↓

Bank / Investment Fund / Capital Markets

↓

Spanish Banking + Securities + Corporate + IP + Regulatory Framework

with EU law operating across several of these layers.

The key point is that nanotechnology itself does not create a special category of banking law. Rather, the technological nature of the business changes the risks that banks, investors and regulators need to evaluate.

Conclusion

Banking law relating to multinational nanotechnology ventures in Spain is best understood as an intersection of financial regulation and advanced-technology law.

The principal banking framework includes Spanish credit-institution legislation, EU prudential requirements and supervision by Banco de España, while securities activities fall principally within the CNMV framework. Spain also has a specific technology-oriented financial sandbox under Law 7/2020, allowing controlled testing of technology-based financial innovation.

For a nanotechnology venture, the most important legal issues are usually:

access to bank and investment finance;

ownership and valuation of intellectual property;

cross-border corporate structure;

foreign investment;

technology and product regulation;

financial-market disclosure;

tax and cross-border financing;

AML and beneficial-ownership requirements; and

data and confidentiality protection.

Relevant jurisprudence includes Spain v Council (C-147/13) on European patent protection, Netherlands v Parliament and Council (C-377/98) and International Stem Cell Corporation (C-364/13) on advanced-technology patent principles, Abraxis Bioscience (C-443/17) on technology-related intellectual-property protection, Commission v Spain (C-463/00) on restrictions affecting foreign investment, and the Banco Popular/Banco Santander resolution cases concerning the interaction between banking regulation and investor rights. These authorities should be treated as relevant legal analogies rather than direct “nanotechnology banking” precedents, because Spanish courts have not developed a separate body of case law under that exact heading.

The central legal challenge for a multinational nanotechnology venture is therefore to align technology ownership, corporate structure, financing, regulatory compliance and cross-border operations so that the company's technological assets can be converted into sustainable financing without creating hidden legal or regulatory risks.